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Abstract
Particle biokinetics is important in hazard identification and characterization of inhaled particles. Such studies
intend to convert external to internal exposure or biologically effective dose, and may help to set limits in that
way. Here we focus on the biokinetics of inhaled nanometer sized particles in comparison to micrometer sized
ones.
The presented approach ranges from inhaled particle deposition probability and retention in the respiratory tract
to biokinetics and clearance of particles out of the respiratory tract. Particle transport into the blood circulation
(translocation), towards secondary target organs and tissues (accumulation), and out of the body (clearance) is con-
sidered. The macroscopically assessed amount of particles in the respiratory tract and secondary target organs pro-
vides dose estimates for toxicological studies on the level of the whole organism. Complementary, microscopic
analyses at the individual particle level provide detailed information about which cells and subcellular components
are the target of inhaled particles. These studies contribute to shed light on mechanisms and modes of action
eventually leading to adverse health effects by inhaled nanoparticles.
We review current methods for macroscopic and microscopic analyses of particle deposition, retention and clear-
ance. Existing macroscopic knowledge on particle biokinetics and microscopic views on particle organ interactions
are discussed comparing nanometer and micrometer sized particles. We emphasize the importance for quantitative
analyses and the use of particle doses derived from real world exposures.
Introduction
It is expected that the use of nanomaterials and primar-
ily of nanoparticulate materials will hold a key position
in future science, technology and medicine. It spans
from automotive, aircraft and space industry, to (bio)
chemical and environmental engineering, to optics, elec-
tronics and communication technologies, to pharmacol-
ogy and medicine, but also to day to day consumer
products, i.e. to food, cosmetics and healthcare. The
introduction of nanoparticulate materials is based on
their exquisite properties and furthered by mandates of
energy and resource savings. In this paper we will not
focus on the manifold beneficial qualities of these new
technologies but examine aspects of concern to pose
risks for consumers and our societies. The exponentially
increasing production of engineered nanoparticles
urgently requires risk assessment of their potential for
adverse health effects. Thereby, data for inhaled
nanoparticles is particularly important because (i) this is
the major route for unwanted exposure, and (ii) there is
ample and consistent evidence for adverse health effects
being associated with increased concentrations of ambi-
ent fine and ultrafine particles (e.g. [1-5]). Also, for
nanoparticles with anticipated beneficial use, e.g. as
diagnostic tools or therapeutics in medicine [6,7] health
risk assessment is necessary. Even already tested materi-
als have to be included since nanoparticles tend to have
different properties compared to larger particles of the
same material [8]. Risk assessment comprises exposure
assessment, hazard identification and characterization,
as well as risk characterization. The Scientific Commit-
tee on Emerging and Newly Identified Health Risks
(SCENIHR) of the European Commission emphasized in
its recent report on Risk Assessment of Products of
Nanotechnologies [9] a number of critical factors for
assessing the impact of nanoparticles and health: (i) so
far, exposure assessment for existing nanomaterials is
rudimentary. (ii) hazardous nanomaterials need to be
characterized both “as manufactured” and in the various
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possible forms “as delivered” in bio- and eco-systems,
(iii) the current lack of a generally applicable paradigm
for nanomaterial hazard identification demands a case
by case approach for the risk assessment of
nanomaterials.
Studies in humans or large animal species are limited;
hence we have to resort to rodents to obtain sufficiently
detailed data for risk assessment by inhaled particles
[10].
The focus of this paper is hazard identification and
characterization, which starts with dosimetry, i.e. the
evaluation of the deposition pattern of inhaled particles
and their subsequent dissemination (biokinetics) in the
respiratory tract and the entire organism. Therein
microscopic analyses at the individual particle level pro-
vide detailed information about which cells and subcel-
lular components are targeted by inhaled particles. Such
studies intend to convert external exposure to internal
exposure or biologically effective dose, and may help to
set limits in that way.
We present and discuss primarily the results from stu-
dies we performed on the deposition, retention and
clearance, as well as on secondary organ translocation of
(insoluble) nanoparticles at a macroscopic and a micro-
scopic level in view of contributing to nanoparticle char-
acterization and identification of their potential risk. We
compare data from inhaled nanoparticles (particles ≤
100 nm in diameter) with those from micrometer-sized
particles with diameters from 100 nm up to 10 μm.
However, due to the blurred upper size limit of nano-
particles we consider micrometer-sized particles as
those in the range of 0.5 - 10 μm. In addition, we
include detailed methodological information allowing
the application of protocols by the interested reader.
Methods
Methods for macroscopic studies
Quantitative biokinetics
Quantitative biokinetics can be performed after nano-
particle administration by any route: by inhalation or
intratracheal instillation to the respiratory tract, by
gavage to the gastro-intestinal tract, by intravenous or
intra-arterial injection to the blood circulation and by
dermal applications to the skin. The concept is simple,
aiming to estimate the total amount of nanoparticles in
the entire body at a certain time point after exposure
and in all excretions until this time point. Hence, not
only the distribution of nanoparticles in organs and tis-
sues of interest is assessed, but nanoparticles in the
remaining carcass and those excreted are also included.
With this, a 100% balance to the administered nanopar-
ticles is achieved and a complete, yet detailed, quantita-
tive analysis of their biokinetics is obtained [11,12]. For
this purpose, particle distribution is measured at several
time points after particle exposure, as shown in Figure
1. Although this approach is applicable to any animal
species, ethical, economic and practical reasons restrict
quantitative biokinetics to small laboratory animals.
Figure 1 Concept of quantitative nanoparticle biokinetics. Nanoparticles (NP) are administered at time t = 0. From this time point on, the
entire urinary and fecal excretions are collected separately. Animals are euthanized at times t1, t2, t3, etc., and organs and tissues of interest as
well as the entire remaining carcass are sampled (100% balanced sampling). Samples require special preparation before chemical analysis, e.g. by
inductive-coupled-plasma mass spectroscopy (ICP-MS). When nanoparticles are radio-labeled, samples will be analyzed directly, without any
further preparation. Reprinted with permission from [21].
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Analytical chemistry e.g. inductively coupled plasma
mass spectroscopy (ICP-MS) or atomic absorption mass
spectroscopy (AA-MS) provides suitable methods to
quantify particles in the collected specimens. Thereby,
special attention has to be paid to sample preparation, i.
e. when nanoparticles need to be dissolved, the extre-
mely low content of ions resulting from the very low
nanoparticle mass may lead to substantial ion loss to
the walls of the reaction vessels prior to sample analysis.
Radio-spectroscopy may provide an elegant alternative,
allowing direct analysis of native organs and tissues
without any pre-treatment. In this case, the radio-label
needs to be firmly integrated into the nanoparticle
matrix without any leaching. While this requirement is
hard to fulfill, when a radio-isotope is blended into the
nanoparticles during production, stable labeling is
obtained, when the radio-isotope belongs to the same
chemical element as the nanoparticle matrix. The latter,
requiring integration of the radio-label during nanopar-
ticle production, however, is often difficult, since nano-
technology laboratories are usually not equipped with
radio-chemistry instrumentation and the necessary per-
mission. Nuclear reaction within the beforehand gener-
ated unlabeled nanoparticles upon neutron, proton or
any other ion bombardment, allows radio-activation of
one to a few atoms of the nanoparticles. Mostly, the
amount of radioactivity is sufficiently high for subse-
quent radio-analysis, when a single atom per nanoparti-
cle was converted by the nuclear reaction. A well known
example is gold that is neutron-activated in a nuclear
research reactor such that the gold nanoparticles are
labeled with the 198Au radio-isotope.
Animals and organ preparation
For our studies with radio-labeled nanoparticles [12,13],
the deeply anesthetized (isoflurane 5%) rats were killed
by exsanguinations via the prepared abdominal aorta.
Like this, about 70% of the total blood volume, esti-
mated from the body weight, was collected. All organs
and tissues, the remaining carcass as well as the total
excretions were thereafter sampled for radio-analysis:
- Organs: lungs, liver, spleen, kidneys, reproductive
organs, brain, heart, gastro-intestinal tract, blood, skin
- Tissues: samples of muscle and of bone (femur)
- Remainder: carcass beyond the listed tissues and
organs
- Excretions: urine and feces, collected separately
To avoid any cross contamination, the organs were
collected in toto and all body fluids were immediately
removed, when vessels or excretory ducts had to be cut.
Organs and tissue samples as well as the entire excre-
tion were collected such that the entire organism was
sampled and weighed in wet state.
The application of clean dissection techniques is
essential to avoid cross contamination, in particular in
inhalation studies, where fur contamination occurs upon
whole body or nose-only exposures. Systematic changes
of dissection tools and equipment are highly recom-
mended. In addition, whole body vascular perfusion to
empty the blood vessels within the organs is recom-
mended to estimate particle retention in the
parenchyma.
Methods for microscopic studies
Analysis of nanoparticles at the individual particle level
by electron microscopy requires (i) adequate organ pre-
servation, (ii) representative tissue sampling, and (iii)
unambiguous identification of the nanoparticles in ultra-
thin tissue sections.
Lung fixation
The methods for tissue preservation using chemical fixa-
tive solutions are well established. The following meth-
ods are generally used for whole lung fixation:
Airway instillation
The fixative is introduced into the airways of a collapsed
lung, in deeply anaesthetized animals or in cadaver
lungs [14]. Thereby, the air spaces evenly expand and
the interalveolar septa remain unfolded. Note: Airway
instillation of (aqueous) fixatives does not preserve the
lung lining layer and luminal cells, i.e. macrophages are
dislocated from their native positions [15].
Vascular perfusion
Fixatives are delivered to the lungs via the blood vessels,
while the airways and alveoli remain in their natural air-
filled state [14,16]. This method is less effective in larger
airways and especially of large animals, due to larger
distance between vasculature and airway surface. Note:
Fixation solely with glutaraldehyde, paraformaldehyde,
or mixtures thereof, does not adequately preserve the
lung lining layer and its associated luminal cells.
Osmium tetroxide and uranyl acetate are necessary for
cross-linking and stabilizing this layer [17,18].
Other methods
Vapor fixation of lungs at a given pressure is a fast and
technically easy method to preserve whole lungs (e.g.
[19,20]). However, shrinkage and organ distortion occur
and ultrastructural preservation of cells is inferior. Non-
polar fixatives, i.e. 1% osmium tetroxide dissolved in
inert fluorocarbon (FC, Fluorinert™ Liquid, 3 M, Bel-
gium) are suitable to preserve large airways, either by
immersion of excised specimens (Figure 2, [21]) or by
airway instillation [17,22,23]. A variety of other fixation
techniques have been developed in view to preserve the
inner surface of airways and alveoli, but most of them
cannot be used to fix whole lungs or even lung lobes
(for review, see e.g. [17]).
Recovery of phagocytic cells by bronchoalveolar lavage
Particle uptake by airway and alveolar macrophages can
be studied in two ways: (i) by fixing whole lungs or
parts thereof to study the cells in situ, within their
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Figure 2 Micrographs of horse trachea fixed by immersion in non-polar fixative (A, B). Note that the lung lining layer (aqueous phase
[asterix] and surfactant film at the air liquid interface [arrow]), has been preserved with this fixation technique. EP = epithelium, CI = cilia. Bars:
(A) = 2 μm, (B) = 0.2 μm. Reprinted with permission from [21].
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functional environment [24-26]; the cells’ location on
surfaces requiring special fixation protocols (see above);
(ii) by isolating the cells from the organ and further pro-
cessing for microscopic analysis; the lung surface cells
being readily accessible to bronchoalveolar lavage (BAL).
In small laboratory animals, surface cells are usually
recovered by whole lung lavage. In humans, BAL cells
are recovered from the lower respiratory tract (bronchi,
bronchioli and alveoli) using flexible fiberoptic broncho-
scopy. The standard site of sampling is generally the
middle lobe or lingula. Note: Not all macrophages will
be recovered by BAL, and it is not known, whether
these macrophages form a distinct population [27].
Morphological characterization and elemental
microanalysis of nanoparticles
Unambiguous identification of nanoparticles in ultrathin
tissue sections is a prerequisite and requires in most
cases their morphologic classification as well as elemen-
tal microanalysis. Particle morphology is established (i)
on aerosol samples collected directly on formvar coated
tsansmission electron microscopy (TEM) grids using
electrostatic precipitation and (ii) on ultrathin sections
of aerosol samples collected on filters (Figure 3). Like
this, the morphology of nanoparticles in 3 d as well as
in 2 d (transects) is established.
Because there are other structures in the ultrathin tis-
sue section that resemble the particles morphologically
("false positives”), additional elemental microanalysis of
the nanoparticles by energy filtering transmission elec-
tron microscopy (EFTEM) (e.g. LEO 912, Zeiss, Oberko-
chen, Germany) is necessary. We have adapted three
high resolution and sensitivity methods for elemental
analysis of TiO2 nanoparticles in ultrathin sections [28],
from which we routinely use electron spectroscopic ima-
ging (ESI), where images are taken at a defined energy
loss. Elemental (titanium) mapping is achieved with the
three window method (Figure 4).
Systematic uniform random tissue sampling and particle
quantification
To investigate the spatial and temporal distribution of
particles in cells, tissues and organs quantitatively, speci-
men selection must confine to some randomness, i.e.
ensure that every part of the organ and every orientation
of a structure or particle therein have the same chance of
being selected [29]. Systematic uniform random sam-
pling, where the first item is selected at random position
and orientation and the following ones in a predeter-
mined interval, is most efficient and is superior to ran-
dom sampling. Specimens for microscopic analysis are
usually sampled in a hierarchical mode, called multistage
or cascade sampling [30]. We have developed the 4-stage
sampling protocol shown in Figure 5 for electron micro-
scopic analysis of nanoparticles in lungs [26,31]. The last
sample consists of fields, delimited by the bars of the hex-
agonal TEM grids, sampled on ultrathin sections of tissue
or cell pellets. These hexagonal fields are then analyzed
for the presence of particles with matching morphology
and material properties. In case of inhaled 20 nm TiO2,
the particles have to correspond to transects of the aero-
sol particles and to consist of titanium upon elemental
microanalysis [26,31,28]. Next, the nanoparticles are
assigned to the compartments of interest.
Recent methods for quantifying nanoparticles using
TEM sections have been reviewed in detail by Mayhew
Figure 3 Nanoparticle morphology. Section profiles (transects) of TiO2 nanoparticles collected from the aerosol on filters, embedded in Epon
and cut perpendicularly to the filter. Note that the as 20 nm measured TiO2 aerosol particles are already agglomerates of smaller primary
particle structures of 3 - 5 nm formed immediately after spark ignition and condensation. Bar: 200 nm.
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and colleagues [32]. Therein, especially the methods for
relative quantification of nanoparticles allowing
between-group and within-group between-compartment
comparisons are readily applicable and have been used
already [e.g. [31,33,34]]. They are usually performed
using particle transect counts on ultrathin sections.
Methods for absolute quantification counts are per-
formed in 3-dimensional space, using pairs of physical
sections, the physical disector, or pairs of optical
sections in a thick section, the optical disector (e.g.
[35-37]). We have implemented this technique to count
micrometer sized particles and airway macrophages in
lungs by light microscopy (e.g. [25,38]). The use of (phy-
sical or optical) disectors for total number estimates of
inhaled nanoparticles, however, is currently not practic-
able in electron microscopy, foremost because of the
high magnification required for particle identification,
but also because of the low number of particles that
Figure 4 Elemental microanalysis of a particle in lung tissue by electron spectroscopic imaging (ESI, three window method),
demonstrating that the nanoparticles (arrows) consists of titanium, adapted from [21]. The first image (A), taken at 0 eV, shows the
structural details; it is slightly shifted as compared to the images used for elemental microanalyses (B-D). For elemental microanalysis, three
images are taken: two below the element-specific edge in order to extrapolate a background image, at ΔE = 390eV (not shown) and ΔE = 440eV
(B), respectively, and one image within the maximum of the element specific signal at ΔE = 464eV (L2,3 edge of titanium) (C). The net titanium
signal (D) is calculated by subtraction of the extrapolated background image from the titanium specific signal. ESI images have reversed contrast
as solely inelastically scattered electrons are used with an energy loss producing a dark field image. Hence, the obtained image reflects the
titanium distribution in white pixels. Bar: 500 nm.
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penetrate into the lung tissue [26]. The latter is also the
reason why electron tomography that allows the applica-
tion of the advanced stereological tools described above
can currently not be used in realistic inhalation studies.
Particle deposition and biokinetics
Particle deposition and lung anatomy
The mechanisms, the pattern and the efficiency of parti-
cle deposition in the respiratory tract largely depend on
the aerodynamic or thermodynamic diameter of the
inhaled particles (Figure 6). Nanoparticles deposit with
high efficiency in the entire respiratory tract, from the
head airways to the alveoli, due to diffusion. Therefore,
only their thermodynamic diameter is relevant during
inhalation; the aerodynamic diameter remains irrelevant,
because sufficiently strong drag forces are absent.
The Human Respiratory Tract Model (HRTM) of the
International Commission of Radiological Protection
(ICRP) provides deposition data of inhaled particles
from 1 nm to 10 μm of healthy adult female and male
human subjects, at different breathing patterns and phy-
siological activities [39]. Data are given for the
Figure 5 Multistage tissue sampling design for EFTEM analysis of nanoparticles, adapted from [21]. Stage 1 - Lung slices: exhaustive
cutting of agar embedded lung lobes (with random start) into equally thick slices [38], followed by systematic sampling of slices, e.g. every
second (with random start) and Epon embedding. Stage 2 - Tissue blocks and ultrathin sections: systematic sampling (with random start) of tissue
blocks from lung slices using a point counting test system and cutting of ultrathin (≤ 50 nm) sections, which are placed on 600-mesh hexagonal
copper grids and stained with lead citrate and uranyl acetate. Stage 3 - Quadrats on ultrathin sections: generation of a virtual field, completely
contained within the ultrathin section, at 80× magnification. Field subdivision into a predetermined number of uniform quadrats and systematic
subsampling of quadrats thereof (marked in grey). Stage 4 - Fields for nanoparticle analysis: Subsampling of a group of seven adjacent fields,
delimited by the hexagonal TEM grid bars, within each quadrat at 6300× magnification, using a point counting test system. Tissue analysis
within these hexagonal fields for (i) the presence of particles with matching nanoparticle characteristics and (ii) particle localization within the
compartments of interest. Stages 3 and 4 can equally be applied on ultrathin sections of cell pellets. Alternative to stages 3 and 4 - Fields for
nanoparticle analysis are sampled by picking a random hexagonal field on the ultrathin section as starting point at 80× magnification. From
there on systematic tissue analysis in horizontal and vertical direction, using the automated goniometer of the microscope.
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extrathoracic, the bronchiolar (i.e. sum of bronchi and
bronchioles) and the alveolar regions. These data, which
we recently discussed [40,41], represent a meta-analysis
of the knowledge at the time of their publication; they
are widely accepted and used in many applications. The
deposition data given for children, however, were solely
derived by applying numerical scaling factors to the data
from adults. In fact, there is considerable lack of knowl-
edge on the deposition in infants and children. Further-
more, there is ample evidence for significantly altered
deposition of nanoparticles in patients with lung disease,
due to changes in the breathing pattern and of fine pul-
monary structures (for review [40-42]).
Despite considerable variations in airway and alveolar
size and cellular composition,n as well as substantial
interspecies differences, the airway and alveolar walls
are built of the same basic structural elements (Figure
7A). In view of the inhaled particle these are: (i) the
liquid lining layer consisting of the surfactant film at the
air-liquid interface and the aqueous phase (periciliary
layer and mucus) beneath it, (ii) the mobile cells, i.e.
mainly resident airway and alveolar macrophages sub-
mersed in the aqueous phase; (iii) the highly differen-
tiated epithelium with its basement membrane and (iv)
the subepithelial connective tissue containing the blood
and lymphatic vessels, and further cells of the immune
system. The inner surface of the lungs functions as a
physical, biochemical and immunological barrier, separ-
ating the outside from inside. It is also these structures
deposited particles first interact with.
Particle retention and relocation pathways within the
lungs
The retention of particles starts with their wetting and
subsequent displacement from the air into the aqueous
phase by surfactant (Figures 7B/C); regardless of shape,
surface topography and surface free energy [43-46].
Though experimentally demonstrated yet for microparti-
cles of 1 - 6 μm in diameter and fibers, the same can be
expected for nanoparticles, since this process becomes
even more efficient with decreasing particle size.
In general, microparticles (0.5 - 10 μm, see our defini-
tion in the Introduction) remain on the epithelial sur-
face in airways and alveoli and are accessible to BAL, as
experimentally best demonstrated in rodents [47,48].
Their retention time depends on the deposition site and
on the interaction of the particles with the inner lung
surface. It is short for particles deposited in conducting
airways due to efficient mucociliary and cough clear-
ance, but it increases with airway generation number, as
a consequence of increasing pathway length and
decreasing mucus velocity. While the retention of
microparticles generally does not exceed 24 - 48 h in
rodent airways, there is evidence for prolonged retention
of microparticles in airways of dogs [49] and of both
micro- and nanoparticles in small airways of humans
[50,51], the probability being inversely correlated to par-
ticle size. In the latter studies, a maximum of long term
retention of up to 80% was found for particles ≤ 100
nm. Further evidence for a correlation between geo-
metric particle diameter and prolonged particle reten-
tion in airways was recently obtained from a study
targeting 100 nm carbon particles to human airways by
shallow aerosol bolus inhalation [42,51]. In this study
only 25% of the nanoparticles were removed by muco-
ciliary clearance within 24 h, while 75% were retained
for more than 48 h. Possible explanations for these find-
ings are that the particles were no longer accessible to
mucociliary clearance either because they penetrated
through the mucus deep into the periciliary phase
[43,46], or that they were deposited in areas with
Figure 6 The respiratory tract (A) and particle deposition in a normal adult mouth breathing male human subject at rest, as a
function of particle size (B). Data of bronchi are the sum of the deposition in bronchi and bronchioles. Adapted from [105] and [39] and
reprinted with permission from [21].
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reduced lung lining layer. In both cases, further interac-
tion of particles with cells of the inner lung surface, i.e.
macrophages, dendritic and epithelial cells is furthered
[52], and the probability for particle relocation beyond
the epithelial barrier enhanced.
Well known and recognized is the interaction of parti-
cles with lung surface macrophages. As we discuss in
detail in the subsequent section, phagocytic uptake of
particles is a key factor for particle clearance in airways
and alveoli, also contributing to particle retention. Evi-
dence for relocation of microparticles to interstitial sites
and long term retention was obtained from biokinetics
and subsequent morphologic studies in dogs [50,53].
There are only few in vivo data of nanoparticles retained
within the lung tissue. We found 20 nm TiO2 nanopar-
ticles, though a small fraction, to penetrate into epithe-
lial cells and deeper into the lung tissue within only 1 h
after aerosol inhalation in rats [31]. From this electron
microscopic study, there was no evidence for substantial
accumulation of nanoparticles in the lung tissue within
24 h post aerosol inhalation. Evidence for considerable
particle relocation into the pulmonary tissue over a
longer period of time, however, was obtained in a six
month study in rats that had inhaled 20 nm iridium par-
ticles during 1 h [12,13]. In this study, as shown in
Table 1, 46% of the nanoparticles were accessible to
exhaustive BAL immediately after aerosol inhalation;
most of them (78%) were not associated with macro-
phages. At 24 h and later, only about 10% of the nano-
particles were accessible to BAL, and from 72 h on
most of them (90%) were associated with macrophages.
It is not yet known by how much the material deter-
mines the extent of particle relocation into cells and
beyond epithelial barriers. For clarification of the
observed differences between TiO2 and iridium nano-
particles described above, additional studies of iridium
nanoparticles at the individual particle level, i.e. by (EF)
TEM, and of the biokinetics of adequately labeled TiO2
nanoparticles are required.
As a result of the relocation of particles from the lung
surface into the pulmonary tissue, such particles may
become accessible to lymphatic drainage and they may
enter blood vessels favoring subsequent dissemination
into secondary organs. Surprisingly, a rather small frac-
tion of microparticles retained in the interstitial lung tis-
sue in dogs was cleared to the hilar lymph nodes, and
there was no detectable particle translocation into the
blood circulation during the entire retention period
[50,53]. Though not studied, macrophage mediated re-
appearance of microparticles on the lung surface for sub-
sequent transport towards the larynx was suggested, as
more than 90% of the microparticles were found to be
associated with BAL macrophages at any time after inha-
lation. In our 24 h study with TiO2 nanoparticles in rats
lymphatic drainage was not assessed and very few parti-
cles were found to have penetrated into the blood vessels
[31]. Furthermore, in the above mentioned study with iri-
dium in rats [12,13] there was no noticeable accumula-
tion of nanoparticles in tracheal lymph nodes and little
translocation into the blood, as altogether about 10% of
the deposited nanoparticles were found to be retained in
all secondary target organs, the skeleton and soft tissue
[54]. Instead, and as observed for microparticles retained
in the interstitium of dog lungs, the long term retained
iridium nanoparticles apparently re-appeared on the
epithelium. And again, subsequent macrophage mediated
clearance to the larynx is likely, since more than 90% of
the iridium nanoparticles were associated with BAL
macrophages at and beyond 72 h after aerosol inhalation.
Particle transport towards the larynx
Conducting airways
The major pathway for particle clearance from conduct-
ing airways is by mucociliary transport. The transport
Figure 7 Components of the inner surface of the lungs (A);
particle deposition and immediate wetting (B) and complete
displacement (C) of the deposited particle (white sphere) into
the lung lining layer by surfactant. Reprinted with permission
from [21].
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rate depends on both the cilia and the lung lining layer;
it is fastest in the central airways and gets slower with
increasing airway generation (for review [50]).
In rodents, microparticles in airways are usually
cleared within 24 - 48 h and the clearance of nanoparti-
cles seems to be fast as well. Kinetic studies with iri-
dium nanoparticles revealed a clearance of about 30% of
the deposited particles within the first 24 h after aerosol
inhalation (rat [11], mouse [55]). The experimental data
in rats correspond rather well with theoretical ones [56];
free public software “Multipath Model of Particle
Deposition, MPPD” is available for particle deposition
and clearance estimates in humans and rats http://www.
thehamner.org/mppd/helpfiles/index.htm. However,
there is evidence that mucociliary clearance may not
remove all particles from the lung surface, particularly
in dogs and humans, resulting in prolonged particle
retention, as we discussed in the previous section. These
apparent differences between species have to be utterly
considered when extrapolating rodent data to man. As
mentioned also in the previous section, the mechanisms
for prolonged retention and, hence, slower clearance of
particles from airways remain unclear. Yet, prolonged
retention favors accumulation of inhaled material within
the tissue, i.e. leads to increased lung burden, which
may be a factor for small airway cancer development. In
fact, the HRTM model of the ICRP already included the
element of prolonged airway retention.
Resident macrophages also contribute to the clearance
of particles from conducting airways. Data from studies
in hamsters with particles of 3 - 6 μm in diameter and of
different materials, showed an average uptake of 28% (SD
16%) of particles deposited in airways by macrophages
within less than 1 h after aerosol inhalation and of more
than 80% of the remaining particles at 24 h [24]. From
this study there was also evidence for rapid (mucociliary)
clearance of macrophages with high particle loads.
Respiratory bronchioles and alveoli
Particle uptake by resident surface macrophages and
further transport to the larynx is the predominant
mechanism for particle clearance from the peripheral
lungs. As in the conducting airways, the internalization
of microparticles is rapid and essentially complete
within 24 h [25,57,58].
The transport rate of microparticles, i.e. their clear-
ance from the lungs varies between species; it is one
order of magnitude lower in man, monkey, dog and gui-
nea pigs than in rodents and sheep [50,59]. One anato-
mical feature of the lung, i.e. the number of generations
of respiratory bronchioles correlates rather well with
these observed species specific differences: rat, mouse,
hamster and sheep have 0 - 2 generations of respiratory
bronchioles, whereas man, monkey and dog have 3 - 5
[60]. There is one exception: the particle clearance rate
is slow in guinea pigs, although they have only about
one generation of respiratory bronchioles. Species speci-
fic differences in particle relocation from the surface
into the lung tissue, as discussed in the previous section,
may also contribute to the observed variations. Respec-
tive correlations can be deduced from experimental stu-
dies with microparticles, which are transported to the
interstitium in human or canine lungs, but remain on
the epithelium in rodent lungs (hamsters: [48,61]).
Effective surface macrophage mediated clearance rates
have been found to be the same for micro- and nano-
particles in rodent lungs [13]. Hence, one could extrapo-
late from both lines of evidence that in human beings
nanoparticles penetrate the lung epithelium for long
term interstitial retention like the microparticles and
consequently the clearance kinetics of nanoparticles is
as slow as that of microparticles. The underlying
mechanisms are not yet fully understood and presum-
ably more complex. Note, however, that due to the very
slow particle clearance kinetics in humans, with declin-
ing particle clearance rates over increasing retention
time, an estimated fraction of 10 - 20% of insoluble par-
ticles will never be cleared out of the human lungs
under physiological conditions [50]. In cases of very
high particle exposure, like in smoking or in some occu-
pational settings (mining, milling, etc.), the fraction of
never-cleared particles may be substantially enhanced
and associated with fibrotic pathogenesis.
We have recently assessed the clearance of inhaled 20
nm TiO2 particles by surface macrophages at the indivi-
dual particle level by EFTEM [26]. The data from this
study in rats showed that surface macrophages do not
efficiently phagocytose these nanoparticles but take
them up rather sporadic and non-specific within the
Table 1 Recovery of inhaled iridium nanoparticles by BAL and association of nanoparticles with BAL macrophages
Time of BAL after aerosol inhalation (h) Particle recovery by BAL
(% lung retention)
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first 24 h after particle inhalation: (i) There was only
about 0.1% of the TiO2 nanoparticles internalized by
macrophages within 24 h after aerosol inhalation, com-
pared to > 10% of microparticles that were phagocy-
tosed already within 1 h [24] and > 80% within 24 h
after aerosol inhalation [38,57,58,62,63]. (ii) As little as
0.2% and 1.7% of the BAL macrophage populations con-
tained nanoparticles at 1 h and at 24 h, respectively,
after the aerosol inhalation, which is about two orders
of magnitudes less than what was shown for 3 - 6 μm
particles of different materials [24,25]. (iii) The TiO2
nanoparticles in BAL macrophages were not tightly
enclosed by the vesicular membrane, as it is known
from phagocytic uptake of microparticles. Instead, nano-
particles were located in large vesicles that mostly con-
tained other material (Figure 8). This also points to a
rather sporadic uptake of TiO2 nanoparticles by surface
macrophages, maybe during the process of phagocytic
uptake of other material. Hence, there is evidence from
these studies that, at least within the first 24 h after
aerosol inhalation, nanoparticles bypass the most impor-
tant clearance mechanisms for particles deposited in the
alveoli, namely phagocytic uptake by surface macro-
phages. Consequently, the probability of uptake by
epithelial cells and/or relocation through the thin
epithelial barrier increases for nanoparticles.
Despite all the variations discussed above, the main
pathway for particle clearance in airways and alveoli, for
free and phagocytosed particles, for micro- and nano-
particles, is towards the larynx. Even particles that were
relocated into the underlying interstitium seem to reap-
pear again on the lung surface to be cleared this way.
Other particle clearance pathways
Particle clearance via the lymphatic system
Particle clearance through lymphatic drainage may be
expected in lungs where significant particle retention in
the interstitial space has been shown, i.e. microparticles
in dogs and iridium nanoparticles in rats. However, in
dogs only a small, intersubject variable fraction of 1 -
5% of deposited microparticles was found to be drained
to the regional lymph nodes under physiological condi-
tions [50,64]. Though there are no human long term
lymphatic clearance data available, we expect essentially
the same fate for microparticles as in dog lungs, because
of the striking similarities of particle clearance kinetics
in these two species. There was also no noticeable iri-
dium nanoparticles accumulation found in tracheal
lymph nodes of rats [12,13].
Still unclear is the role of bronchus associated lym-
phatic tissue (BALT) by which particles would find their
way back to the airway epithelium, via particle drainage
into the lymphatic vessels and the blood circulation, as
it was hypothesized many years ago [65-67].
Particle transport from the interstitium onto the epithelial
surface
As discussed above, there is evidence for re-appearance
of microparticles on the lung epithelium in dogs and
humans, and of nanoparticles in rodents, because the
most prominent clearance pathways of long term (in the
interstitium) retained particles were shown to be surface
macrophage mediated and directed towards the larynx
(dogs [53], rats [13]). This clearance pathway is obsolete
in rodents, which have negligible interstitial retention of
microparticles [48,61]. So far there are no human or
large species data available on the long term retention
and clearance of insoluble nanoparticles from the per-
ipheral lungs. The re-appearance of nanoparticles on the
lung epithelium from the interstitium is likely to be
macrophage mediated. As discussed above, we cannot
yet exclude that particles may also re-appear on the
lung epithelium as a consequence of their release into
the lymphatic vessels from BALT [65-67].
Particle translocation to the blood and accumulation in
secondary target organs
For more than a decade, epidemiological studies have
indicated associations between exposure to increased
concentrations of ambient fine and ultrafine particles
and adverse health effects in susceptible individuals
[1,4,5,68]. Cardiovascular effects observed in these stu-
dies triggered the discussion on increased transport of
inhaled ultrafine particles from the epithelial surface
towards the blood circulation and subsequently to target
organs, like the heart, liver and brain, eventually
adversely affecting the functions of these organs [69].
From the latter review, nanoparticles are apparently
transported across membranes with hardly any restraint,
which has not been reported for microparticles. As a
mechanism, complex formation of nanoparticles with
lung lining layer proteins as such that this complex acts
like a ferry boat for nanoparticles is conceivable. Micro-
particles would be excluded from this transport because
of their larger size [70-72]. In addition, since
Figure 8 TEM micrographs (A) and (B) of inhaled TiO2
nanoparticles (arrows) located in large phagolysosomes, which
contain other phagocytosed material, in mouse surface
macrophages. Bars: 200 nm.
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microparticles are rapidly phagocytosed by lung surface
macrophages, they are only shortly available for protein
mediated transport. Surface modifications of nanoparti-
cles are currently intensely studied in nanomedicine
aiming at managing specific biokinetic behaviors of
nanoparticles to distinctively target organs for diagnostic
as well as therapeutic use [73]. As an example, drug
delivery to the central nervous system via circulating
nanoparticles requires surface modifications allowing
receptor mediated nanoparticle translocation across the
blood-brain barrier. Apolipoprotein-E coating of nano-
particles for LDL receptor mediated endocytosis in brain
capillaries has been discussed [74-76]. Such highly desir-
able properties of nanoparticles must be carefully
weighed against potential adverse cellular responses to
targeted drug delivery by nanoparticles; a rigorous risk
assessment is mandatory.
Nanoparticles not only offer a much larger surface area
to be modified than microparticles of the same mass, but
their larger number allows their dispersion into many
more cells. For instance, a particle mass of 100 ng corre-
sponds to only 2.4 × 104 particles (spheres of unit den-
sity) of 2 μm in diameter, but to 2.4 × 1010 particles of 20
nm, or to 2.4 × 1013 particles of 2 nm. Note that 20 nm
particles comprise a major fraction of the number con-
centration of ambient aerosol particles [77] and that 2 to
10 nm particles are the primary particles originating
from many combustion processes of which aggregated
ambient ultrafine particles are made of.
Assuming that 100 ng of particles have accumulated
in a secondary target organ like the heart or the brain,
this would usually not be considered to be of any toxi-
cological relevance for low toxicity particles. This is par-
ticularly true for the low particle number in the entire
organ, when particles are 2 μm in diameter. However, if
they are 2 nm particles, they exceed the number of cells
in the organ easily by a factor of thousand (cell estimate
is based on a 100 g organ and a cell volume of 4.2 × 10-
9 cm3 corresponding to a cell of 20 μm in diameter).
This enhances the probability of inducing adverse
effects, although other factors like the subcellular locali-
zation of the nanoparticles, their chemistry and surface
characteristics like surface proportional numbers of bio-
chemically reactive centers are contributing as well.
There is plentiful literature on nanoparticle-cell inter-
action studies in vitro, however, the number of particles
per cell was mostly not estimated but only the total
mass added to the cell cultures is reported. In addition,
rough estimates indicate that in most of these studies
the nanoparticles to cell ratio was far beyond 1000:1,
which largely exceeds any realistic dose in vivo. In many
in vitro studies, particles are applied in doses of 1 - 100
μg per 105 cells. Assuming the application of the lowest
dose of 1 μg particles per 105 cells and the use of
spherical nanoparticles of unit density and a size of 50
nm, 2 × 105 nanoparticles per cell, or 2 × 1010 nanopar-
ticles per 105 cells, are applied. However, the effective
dose per cell is very difficult to estimate, since these
nanoparticles will not precipitate in the cell culture
medium because of their minimal mass, but move by
Brownian motion (diffusion), which is a non-directed
motion. In addition, particle diffusion favours agglom-
eration to larger particle structures, which will then pre-
cipitate. By the time they do so, the particle
characteristics, i.e. size distribution and concentration
have obviously massively changed.
To estimate exposure conditions in vivo, we may
assume an inhaled daily air volume of 15 m3 for a
healthy, adult, moderately active individual [39], a num-
ber concentration of ambient air particles of 3 × 104/
cm3, whereof 80 - 90% are nanoparticles [77], and a par-
ticle deposition fraction of 0.3 [39]. The first exposure
estimate results in 1.4 × 1011 nanoparticles being depos-
ited per day or 6 × 109 particles deposited per hour.
Even if particle number concentrations are higher, there
is a maximal possible daily deposition of nanoparticles
because of aerosol-physical limitations mostly due to
diffusional coagulation. It is not possible to maintain the
number concentration of nanoparticles aerosols above 1
× 106/cm3 for more than several minutes under normal
ambient conditions. Hence, under such conditions maxi-
mally 2 × 1013 nanoparticles per day or 6 × 1011/cm3
per hour can be inhaled by an adult human. To estimate
the ratio of nanoparticles per cell in vivo, we focus on
the lung periphery, which is by far the largest compart-
ment for nanoparticle deposition. We assume the alveo-
lar surface of about 1402 m in humans to consist of 2 ×
1010 epithelial type I cells and 3 × 1010 epithelial type II
cells, and to contain 6 × 109 alveolar macrophages [78].
Hence, for breathing of ambient aerosols, on average 6
nanoparticles will be daily deposited per cell in the
alveolar region. Maximally, but not realistic, at the high-
est possible nanoparticles aerosol number concentration
of 1 × 106/cm3, an alveolar surface cell will receive on
average 120 nanoparticles per hour. Even if we consider
a maximum factor of 20 for inhomogeneous deposition
beyond an otherwise rather homogeneous diffusional
deposition in the peripheral lungs, the nanoparticle dose
to some surface cells may increase by this factor at
most.
For in vitro studies to become more relevant for asses-
sing health effects by inhaled particles the nanoparticle
dose per cell should reflect real exposure conditions
[79].
Experimental studies on nanoparticle biokinetics
Human studies
Comprehensive biokinetics analysis of nanoparticles
accumulation and retention in organs and tissues is not
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feasible in humans; because of ethical, but also technical
reasons due to limiting resolution of existing imaging
detection systems from outside the body or for body
fluid samples.
So far, there is no evidence for a translocated nano-
particle mass fraction of more than 1% of the dose
delivered to the lungs from reliable studies in humans
[42,80-83]. However, there is indirect evidence of nano-
particle translocation in humans from recent inhalation
studies in healthy subjects with diluted Diesel exhaust,
which was found to impair the regulation of the vascular
tone and fibrinolysis [84]. In addition, in a similar study,
spontaneous alterations of electroencephalogram (EEG)
signals in the frontal cortex were observed during and
up to 1 h after exposure to Diesel exhaust [85]. From
these studies it is not clear, whether the observed effects
were initiated by translocated nanoparticles or by med-
iators released from the lungs in response to interac-
tions with deposited nanoparticles.
Until now, histopathology revealed substantial particle
loads in secondary target organs only after long term
and massive exposure to microparticles; e.g. tar accumu-
lation leading to increased blackening of lungs in smo-
kers, particle or fiber accumulation in the liver and
other organs of the reticulo-endothelial system in coal
miners and asbestos workers [86,87]. Thereby, particle
transport from the interstitium to the lymphatic system
and further into the blood circulation was assumed.
Similarly, in overload conditions translocation and accu-
mulation of microparticles particularly in reticulo-
endothelial organs were observed in experimental ani-
mals (dogs [88], rodents reviewed by [89]).
Animal studies
There is evidence for translocation of gold, silver, TiO2,
polystyrene and carbon nanoparticles in the size range
of 5 - 100 nm across the air-blood barrier from animal
experiments. Either, nanoparticles were found in the
blood circulation [31,90] and in secondary target organs
[11-13,91-94], or thrombogenic effects were observed
[95-97]. However, it still remains unclear, whether the
translocated particle fractions exceeded 5% of the deliv-
ered lung dose (see also [41,98]). Recently, Chen and
colleagues [99] reported an estimated translocated frac-
tion of 1 - 2% for 50 and 200 nm polystyrene particles.
Quantitative assessment of nanoparticle translocation
Quantitative particle biokinetics as described in the
Methods section allows the precise estimate of total and
organ specific translocated nanoparticle fractions. Such
data are currently available for:
- Inhaled iridium nanoparticles, 20 and 80 nm in dia-
meter, in rats and mice [11-13]
- Inhaled carbon nanoparticles, 25 nm in diameter,
spiked with radio-labeled primary iridium nanoparticles
in rats [54]
- Instilled gold nanoparticles, 1.4 and 18 nm in dia-
meter, in rats [94,100].
From the inhalation studies with iridium nanoparticles
it became clear that such particles accumulate not only
in secondary target organs but also in soft (connective)
tissue and skeletal bone including bone marrow. In
these studies, accumulation of 20 nm particles in all sec-
ondary target organs (liver, spleen, kidneys, heart, brain,
reproductive organs) was in the range of 1 - 2% of the
deposited dose at 24 h after administration. A similar
fraction was found in the skeleton and up to 5% in the
soft tissue. Hence, the total translocated fraction of
nanoparticles reached just about 10% [54]. Furthermore,
20 nm iridium nanoparticles were poorly cleared from
secondary target organs such that six months after a
single one hour inhalation exposure, the total fraction of
nanoparticles in all secondary target organs was still
close to 0.1% of those initially deposited in the lungs,
and all organs studied still contained nanoparticles
[12,13]. Unfortunately, there are no further data on long
term translocation of nanoparticles yet.
Even in the fetuses of pregnant rats in their third tri-
mester, small but detectable fractions of translocated
nanoparticles were registered [94].
Particle characteristics
Size
There is evidence from experimental studies that the
translocation and accumulation of nanoparticles in sec-
ondary target organs depend on particle size; i.e. inhaled
80 nm iridium particles were shown to translocate
about one order of magnitude less than the 20 nm ones,
including accumulation in the skeleton and soft tissue
[11,54]. Additionally, significant differences in the trans-
location and accumulation between 1.4 nm and 18 nm
gold nanoparticles have been observed, with total trans-
located fractions of 8% and 0.2%, respectively, at 24 h
after their intratracheal instillation [100]; both size cate-
gories were found in all secondary target organs
investigated.
Material
Consequences of different materials on nanoparticle
translocation and 24 h accumulation in secondary
organs can be derived from inhalation studies with 20
nm iridium and 25 nm carbon nanoparticles. The frac-
tion of carbon was significantly, 5 - 10 times lower than
that of iridium (except in the liver) in any of the sec-
ondary target organs studied as well as in the skeleton
or soft tissue. Note that both particle types are chain
agglomerates made up of either 2 to 5 nm iridium or 5
to 10 nm carbon primary particles. Caution is required
when these data are compared with those of 18 nm gold
of similar size: there is not only the material difference,
but gold nanoparticles are spherical and have a smooth
surface. In addition, particle administration to the lungs
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was different (inhalation versus instillation). Yet, the
total difference of almost 10% of translocated iridium
and about 2% carbon chain agglomerates compared to
0.2% of the spherical gold nanoparticles within 24 h is
striking, when considering particle material dependence
only. There are more quantitative data required to bet-
ter understand how particle materials influence
biokinetics.
Dosimetry models for risk assessment
Experimental data help to develop and optimize mathe-
matical models to predict the risk from inhaled particles.
Kuempel and colleagues [101] showed reasonably good
agreement between observed and predicted retained
lung burden of poorly soluble fine and ultrafine particles
in chronically exposed rats using dosimetry models. In
addition, dosimetry models were further optimized to fit
human data [102]. Thereby, the best fitting model was
the one that included interstitionalization of particles,
which is in accordance to the evidence obtained from
experimental studies in humans. Such models can also
be extended to include translocation of particles to sec-
ondary organs or differences in particle characteristics
[103,104].
Summary remarks on nanoparticle translocation across the
air-blood-barrier
Besides the discussed importance of size and material,
other particle characteristics such as the surface charge
(zeta potential) and surface structures are very likely to
influence nanoparticle biokinetics. They determine the
interactions of nanoparticles with proteins and cellular
components and thereby the mechanisms for particle
translocation and accumulation in extra-pulmonary
organs. However, it needs to be emphasized that accord-
ing to current knowledge, nanoparticles translocation
and accumulation in extra-pulmonary organs is a minor
clearance pathway for nanoparticles from the lungs
compared to (long term) macrophage mediated nano-
particle clearance towards the larynx. Yet, while the lat-
ter pathway leads to particle excretion via the gastro-
intestinal tract, nanoparticle translocation into the blood
circulation systemically distributes nanoparticles and
allows access to e.g. the cardio-vascular, the central-ner-
vous and the reticulo-endothelial, i.e. the immune sys-
tems. Despite potential toxicological consequences for
the organism when nanoparticles interact with these
organ systems, it is still unknown whether it is the
translocated nanoparticles that cause the epidemiologi-
cally established adverse effects. Particularly, it remains
to be shown whether chronic exposure leads to suffi-
ciently high nanoparticle doses to trigger or mediate
responses leading to initiation and/or progression of dis-
ease. In addition, the release of mediators into the blood
circulation needs thorough investigations: these media-
tors may be triggered or modulated by the well-known
oxidative stress and pro-inflammatory responses to
nanoparticles. Yet, even the importance of the dose
metric is still debated. If nanoparticle mass is the effect
determining metric, it appears very unlikely that suffi-
ciently high doses in extra-pulmonary organs can be
reached by inhalation. However, if nanoparticle number
and (biochemically reactive) surface are the effect deter-
mining metrics, chronic exposure to nanoparticles may
well be a health hazard; particularly, in susceptible indi-
viduals such as infants, the elderly and individuals with
pre-existing cardiovascular and lung diseases.
Furthermore, the interaction of nanoparticles with the
organism has to be studied at cellular and molecular
levels, in lungs as well as in those secondary target
organs which receive sufficiently high doses. Micro-
scopic analyses of such organs from animal inhalation
experiments may provide more detailed information
about possible pathways responsible for (adverse) effects.
It will be important to know which tissues, cells and/or
subcellular compartments nanoparticles interact with
and what particle properties are crucial for these inter-
actions. Unrestricted crossing of the cellular membranes
by nanoparticles facilitates not only their translocation
into basically any organ but also into cells and subcellu-
lar compartment.
While unexpected nanoparticle access to secondary
target organs at non negligible doses on a macroscopic
scale as well as unexpected nanoparticle access to par-
enchymal and immune cells and to their subcellular
structures like mitochondria and nuclei may result in
adverse health effects, these interactions and pathways
provide unforeseeable opportunities in the design of
nanoparticles for diagnostic or therapeutic medical use
in the new field of Nanomedicine.
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